Bitcoin slips under $63,000 despite Iran deal hopes as Coldcard losses rattle market
Oil and Treasury yields fell after fresh U.S.-Iran talks eased inflation fears, but bitcoin and ether failed to catch a bid as fresh Coldcard-linked sweeps...
BTC
ETH
BNB
ADA
XRP
DOGE
SOL
DOT
BTC
ETH
BNB
ADA
XRP
DOGE
SOL
DOT
BTC
ETH
BNB
ADA
XRP
DOGE
SOL
DOT
BTC
ETH
BNB
ADA
XRP
DOGE
SOL
DOT
Which part of the AI trade is more likely to better serve investors?
Most popular articles this week
Latest news from global stock markets, tech giants, and financial sectors
Browse ArticlesBitcoin, Ethereum, altcoins, DeFi, NFTs, and blockchain technology
Browse ArticlesGold, silver, oil, natural gas, and other precious commodities
Browse Articles
Oil and Treasury yields fell after fresh U.S.-Iran talks eased inflation fears, but bitcoin and ether failed to catch a bid as fresh Coldcard-linked sweeps...
The persistent discount suggests US spot buyers have remained less aggressive than overseas traders even as US Bitcoin ETF inflows turned positive in July.
Wallets tied to the Truth Social parent now hold about as much bitcoin as the company previously pledged as note collateral, making its next 10-Q the key t...
Michael Saylor's company, Strategy, is now closely monitoring bitcoin's 200-week moving average, a key long-term support level that the cryptocurrency has...
The five-year bug escaped detection because auditors verified that the intended random number generator existed, but not that it was being called.
Grok AI predicts a major re-rating for Bitcoin, and this price prediction is unusual in its timeframe, targeting the end of 2027 rather than 2026. From tod...
AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report
WestJet flight attendants go on strike after talks fall through, grounding flights
Young investors can build significant wealth in the stock market by focusing on the long term.
Nvidia could still deliver impressive gains if Wall Street keeps raising its earnings estimates.
The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials.
These 4 topics are central to the success of SpaceX valuation: Bernstein